Kalaris Therapeutics Inc (KLRS)
NASDAQ: KLRS
· Real-Time Price · USD
5.96
0.11 (1.88%)
At close: May 02, 2025, 3:59 PM
5.83
-2.18%
After-hours: May 02, 2025, 04:05 PM EDT
Company Description
Kalaris Therapeutics Inc operates as a pharmaceutical company.
The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Kalaris Therapeutics Inc
| Country | United States |
| IPO Date | Jul 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Andrew Oxtoby |
Contact Details
Address: 139 Main Street, Suite 500 Cambridge, Massachusetts United States | |
| Website | https://kalaristx.com/ |
Stock Details
| Ticker Symbol | KLRS |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 482929106 |
| ISIN Number | US4829291065 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Andrew Oxtoby | President, Chief Executive Officer & Director |
| Dr. Jeffrey Nau MMS, Ph.D. | Chief Operating Officer |
| Brett R. Hagen | Principal Financial Officer & Principal Accounting Officer |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer |
| Dr. Michael Philip Dybbs Ph.D. | Director & Co-Founder |
| Dr. Napoleone Ferrara M.D. | Director & Co-Founder |
| Dr. Samir C. Patel M.D. | Director & Co-Founder |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director & Co-Founder |